A GENE therapy business that spun out of the University of Edinburgh’s Roslin Institute in 2006 has received £1.2 million in government funding to work alongside a Glasgow counterpart to develop clinical-grade stem cells.

RoslinCT, which traded as Roslin Cells between 2006 and 2015, will partner with Glasgow-based ReproCELL UK on the project after receiving the cash from non-departmental body Innovate UK.

A total of £10m was made available via the second round of Innovate UK’s medicines manufacturing competition, which is designed to back projects that focus on specific technical or commercial challenges.

RoslinCT chief executive Janet Downie said the funding would allow the firms to “develop a competitive and disruptive impact on the supply of clinical induced pluripotent stem cells [iPSCs]”.

While iPSCs are considered to be a promising source of cells for regenerative medicine, they have proved difficult to produce for clinical use. RoslinCT and ReproCELL aim to find a way of producing and commercialising them.

ReproCELL chief executive Dr David Bunton added: “When combined with the automation and manufacturing capabilities of RoslinCT, we aim to make it easy for companies with new therapies to rapidly and cost-efficiently enter clinical trials and then scale-up for commercial manufacturing.”